Clinical Trial Update: Baricitinib in Patients With Relapsing or naïve Dermatomyositis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating baricitinib for relapsing or treatment-naïve dermatomyositis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Dermatomyositis | Phase 3 | Status: RECRUITING